Skip to main content
RT @RichardPAConway: Sode et al Mortality in GCA. Dominated by CV disease and higher than controls. Less cancer than con

Richard Conway RichardPAConway

3 years 11 months ago
Sode et al Mortality in GCA. Dominated by CV disease and higher than controls. Less cancer than controls @rheumnow #ACR22 Abstr#0467 https://t.co/TsfTWFRxJ2 https://t.co/lCZgVTpKUY
RT @RichardPAConway: Kaeley et al. Evaluation of success of RA treatment. 69% LDA, 17% MDA, 14% HDA. Common barriers - m

Richard Conway RichardPAConway

3 years 11 months ago
Kaeley et al. Evaluation of success of RA treatment. 69% LDA, 17% MDA, 14% HDA. Common barriers - medication access 27%, non-adherence 20%, co-morbidities 20%, non-inflammatory pain 13% @rheumnow #ACR22 Abstr#0077 https://t.co/c7euuzSx1m https://t.co/9ZN14ph5kI
RT @ericdeinmd: @AlexisOgdie at #ACR22:
Ab0189 Ignite 🔥
PEST screening in patients with PsO w/o diagnosis of PsA - ca

Eric Dein ericdeinmd

3 years 11 months ago
@AlexisOgdie at #ACR22: Ab0189 Ignite 🔥 PEST screening in patients with PsO w/o diagnosis of PsA - captures pts at highest risk. Decrease QoL, higher co-morbdities High sensitivity test for screening But is it capturing other co-morbidities (obesity, depression?) @RheumNow
RT @RHEUMarampa: What factors influence visit preferences in pts w/ rheumatic dse? @rheumarhyme @doktora_ging
Interesti

sheila RHEUMarampa

3 years 11 months ago
What factors influence visit preferences in pts w/ rheumatic dse? @rheumarhyme @doktora_ging Interesting findings by Dr MDanila et al: 👉In-person visits due to org/clinic level influences 👉#telemedicine visits due to individual level influences #ACR22 @RheumNow ABST0193 https://t.co/HcCUeahH8L
RT @DrPetryna: Pregnancy associated back pain and fatigue during 3rd trimester of pregnancy may affect accuracy of BASD

Olga Petryna DrPetryna

3 years 11 months ago
Pregnancy associated back pain and fatigue during 3rd trimester of pregnancy may affect accuracy of BASDAI score in women with AS. Morning stiffness has the highest classification value #ABS0374 #ACR22 @RheumNow https://t.co/DozZ6bxSU3
RT @RichardPAConway: Levinson et al. Comparative risks of Alzheimers in inflammatory diseases. SLE (OR 1.31) and IBD (OR

Richard Conway RichardPAConway

3 years 11 months ago
Levinson et al. Comparative risks of Alzheimers in inflammatory diseases. SLE (OR 1.31) and IBD (OR 1.17) higher risk than controls, RA, or PsO/PsA @rheumnow #ACR22 Abstr#0062 https://t.co/PbRa033e0L https://t.co/ENycKG4cyQ
RT @uptoTate: Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an inte

Dr. Rachel Tate uptoTate

3 years 11 months ago
Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an interesting study yielding more questions than answers. #ACR22 @RheumNow https://t.co/0Q260CGw3r https://t.co/LepPOrq7Gv
RT @RichardPAConway: Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 pa

Richard Conway RichardPAConway

3 years 11 months ago
Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 patients. Sustained remission 78.2% optimised group (vs 66.7%). @rheumnow #ACR22 Abstr#0474 https://t.co/jPRy4RjfJA https://t.co/b1CP8pFwhJ
RT @synovialjoints: Adding MTX to Pegloticase for 52 wks in gout
◦ Improved response rate by 30%
◦ Reduced disconti

Dr. Antoni Chan synovialjoints

3 years 11 months ago
Adding MTX to Pegloticase for 52 wks in gout ◦ Improved response rate by 30% ◦ Reduced discontinuation rate by 40% ◦ Greater resolution of tophi by 20% ◦ Similar safety profile in MTX vs non-MTX groups Botson J MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow
RT @RichardPAConway: Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+.

Richard Conway RichardPAConway

3 years 11 months ago
Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+. Less likely MSK symptoms, granulomatous disease @rheumnow #ACR22 Abstr#0439 https://t.co/Zi7H5UaolS https://t.co/Z04TvugnnE
RT @DrPetryna: #abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNF

Olga Petryna DrPetryna

3 years 11 months ago
#abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNFi&SEC) respond well to IXE after 12 mo even w/monotherapy:IXE mono (82% pts) change in CDAI from BL to 6 mo -3.6 points& 12 mo -4.9 pts (statistically significant for both) https://t.co/5dRk86A9Xr
RT @RichardPAConway: de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west g

Richard Conway RichardPAConway

3 years 11 months ago
de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west gradient @rheumnow #ACR22 Abstr#0475 https://t.co/XDSSrJcMu5 https://t.co/nlJjcPB3zo
RT @uptoTate: Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI

Dr. Rachel Tate uptoTate

3 years 11 months ago
Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI >4, +HLA-B27, female sex, ^ CRP, hx of B ocular involvement. #ACR22 @RheumNow https://t.co/Fg0v6NVQcI
×